GlycoPath Inc. Applies Proprietary Technology to Lyme Disease to Distinguish Among Disease States and Track Treatment Response
KOIN 6,
CHARLESTON, S.C., Oct. 21, 2022 /PRNewswire/ -- GlycoPath's proprietary GlycoTyper™ immunoaffinity technology was used to…